Water-Insoluble Antibiotic Conjugate Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for infections involving biofilms, such as those in prosthetic joint infections, are inadequate due to the high resistance of biofilms to antibiotics, leading to unpredictable treatment success, potential for bacterial drug resistance, and significant health and economic burdens.
Innovation Solution
A water-insoluble conjugate comprising a polymeric moiety covalently conjugated with antibiotic moieties via reversible linkers, designed for sustained release to maintain antibiotic concentrations above the minimal biofilm eradication concentration for at least 3 days post-intra-articular injection, ensuring prolonged exposure to antibiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of antibiotics are used to treat biofilm infections, then biofilm eradication is achieved, but antibiotic resistance develops and toxicity increases
Solution Approach 1:
The patent employs dynamic, sustained-release antibiotic delivery from the conjugate system, transforming antibiotics from static high-dose administrations into dynamically regulated releases. This maintains therapeutic concentrations over time while avoiding peak doses that drive resistance, directly resolving the contradiction between eradication efficacy and resistance development
Solution Approach 2:
The invention changes the temporal parameter of antibiotic delivery from acute high-concentration pulses to prolonged low-concentration exposure. By modifying the concentration-time profile through reversible conjugation kinetics, the system achieves biofilm eradication at sub-bactericidal levels, eliminating the need for high doses that cause resistance and toxicity
2Object-affected harmful factors
If antibiotic concentrations are kept low to avoid resistance, then toxicity is reduced, but biofilm eradication fails
Solution Approach 1:
The patent implements continuous antibiotic action through sustained release from the conjugate, maintaining therapeutic levels indefinitely rather than relying on intermittent high-dose boluses. This continuous exposure at low concentrations achieves biofilm eradication without the toxicity associated with high-dose regimens
Solution Approach 2:
The dynamic equilibrium of reversible conjugation allows the system to self-regulate antibiotic release, providing continuous therapeutic action at optimal concentrations without requiring high-dose interventions that cause toxicity
3Reliability
If multiple high-dose antibiotic administrations are given, then biofilm eradication is attempted, but treatment duration and healthcare costs increase
Solution Approach 1:
The patent prepares the conjugate system in advance with multiple antibiotic moieties attached, creating a reservoir that releases drugs over time. This preliminary loading eliminates the need for repeated administrations, reducing treatment duration while maintaining eradication efficacy
Solution Approach 2:
The sustained-release conjugate provides continuous therapeutic action from a single administration, replacing multiple discrete treatment sessions. This continuous delivery maintains effective concentrations throughout the treatment period, achieving eradication faster than intermittent high-dose regimens
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate achieves sustained antibiotic release, effectively eradicating biofilms with lower concentrations over time, reducing the risk of resistance and improving treatment outcomes for joint infections.
Implementation Method 1
each -L1- is independently a linker moiety to which -D is covalently and reversibly conjugated
Data Source
AI summary
The present invention relates among other aspects to a conjugate or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said conjugate or its pharmaceutically acceptable salt for use in a method of preventing or treating an infection, wherein said conjugate is water-insoluble and comprises a polymeric moiety —Z to which a plurality of moieties -L2-X0D-L1-D are covalently conjugated, wherein each -D is independently an antibiotic moiety; each -L1- is independently a linker moiety to which -D is covalently and reversibly conjugated; each —X0D— is independently absent or a linkage and each -L2- is independently either a chemical bond or a spacer moiety.